Targeted therapy to manage kidney complications may enable continuation of lifesaving immunotherapy

Immune checkpoint inhibitors (ICIs) have transformed treatment for many types of cancer. In some patients, however, ICIs are associated with immune-related complications that can affect the kidneys. These complications sometimes require care teams to pause or discontinue lifesaving treatment. A stud